Immunomedics Inc. said it has successfully used its directlabeling technology to bind a potent beta-emittingradioisotope, rhenium-188, to a monoclonal antibody againsthuman colorectal cancer.
The Warren, N.J., company reported its success in micecontaining human colorectal cancers in the Sept. 1 issue ofCancer Research.
Immunomedics plans to begin Phase I clinical trials in thefirst half of 1992.
Immunomedics has used the labeling technology in cancerdiagnostics. But its diagnostic isotope, technetium-99, isn'tpotent enough to reach and destroy colorectal cancers, aspokesman said.
The company' stock (NASDAQ:IMMU) closed at $10.50, up $1.13,on Friday.
(c) 1997 American Health Consultants. All rights reserved.